Provided by Tiger Trade Technology Pte. Ltd.

Anavex Life Sciences

4.10
+0.29007.61%
Volume:1.68M
Turnover:6.91M
Market Cap:366.33M
PE:-7.54
High:4.26
Open:3.86
Low:3.82
Close:3.81
52wk High:13.99
52wk Low:2.86
Shares:89.35M
Float Shares:83.05M
Volume Ratio:0.98
T/O Rate:2.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5438
EPS(LYR):-0.5438
ROE:-43.11%
ROA:-26.51%
PB:3.86
PE(LYR):-7.54

Loading ...

Company Profile

Company Name:
Anavex Life Sciences
Exchange:
NASDAQ
Establishment Date:
2004
Employees:
34
Office Location:
630 5th Avenue,20th Floor,New York,New York,United States
Zip Code:
10111
Fax:
- -
Introduction:
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Directors

Name
Position
Christopher Missling
Chief Executive Officer,Director, President and Secretary
Jiong Ma
Chair and Director
Athanasios Skarpelos
Director
Claus van der Velden
Director
Peter Donhauser
Director
Steffen Thomas
Director

Shareholders

Name
Position
Christopher Missling
Chief Executive Officer,Director, President and Secretary
Sandra Boenisch
Principal Financial Officer and Treasurer